Phase 1b trial shows good response rate
Individual tumor DNA may be key
Cleveland Clinic urologist performs first procedure in Europe
Response to larotrectinib “almost miraculous”
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Established lymphoma/leukemia therapy also targets glioma stem cells
Exploring the benefits of proactive, multidisciplinary care
Researchers refining computer program for greater accuracy
Formula works best for exophytic tumors
Cardiac dosing 50 percent below national average
Two Cleveland Clinic physicians lead the way
Advertisement
Advertisement